系统性硬化症左心室收缩功能障碍的临床病程和预测因素:一项队列研究。

Rheumatology and immunology research Pub Date : 2024-07-15 eCollection Date: 2024-06-01 DOI:10.1515/rir-2024-0014
Jakrapan Werakiat, Burabha Pussadhamma, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Chingching Foocharoen
{"title":"系统性硬化症左心室收缩功能障碍的临床病程和预测因素:一项队列研究。","authors":"Jakrapan Werakiat, Burabha Pussadhamma, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Chingching Foocharoen","doi":"10.1515/rir-2024-0014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Left ventricular systolic dysfunction (LVSD) is a cardiac involvement that is the leading cause of death among patients with systemic sclerosis (SSc). We aimed to define the clinical course and predictors of LVSD among SSc patients.</p><p><strong>Methods: </strong>We conducted a cohort study among adult patients with SSc who were followed up from 2013 to 2020. Semiparametric Cox regression analysis with robust clustering by cohort identification number was used to evaluate the predictors of LVSD.</p><p><strong>Results: </strong>Among the 3, 987 person-years, LVSD was defined in 35 of 419 SSc patients for an incidence of 0.88 per 100 person-years. The median duration of the disease was 8.5 (interquartile range (IQR) 4.9-12.9) years. Every 1-point increase in the modified Rodnan skin score (mRSS) and salt and pepper skin were strong predictors of LVSD, with a respective adjusted hazard ratio (HR) of 1.05 and 3.17. During follow-up, 26 cases (74.3%) had unimproved LVSD. The strong predictors of the unimprovement of LVSD were every 1-point increase in mRSS (HR 1.05), every 1 mg increase in prednisolone treatment (HR 1.05), and every 1 U/L increase in creatine kinase (CK) (HR 1.001). Mycophenolate treatment was a protective factor against the unimprovement of LVSD in SSc (HR 0.15).</p><p><strong>Conclusions: </strong>LVSD was frequently found in patients with diffuse cutaneous SSc, and in most cases, it remained unimproved during follow-up. High mRSS, steroid use, and high CK levels were predictors of unimproved LVSD, whereas mycophenolate treatment might prevent the progression of LVSD. Steroids should be prescribed with caution in patients with longer disease duration.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 2","pages":"107-116"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11248551/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical courses and predictors of left ventricular systolic dysfunction in systemic sclerosis: A cohort study.\",\"authors\":\"Jakrapan Werakiat, Burabha Pussadhamma, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Chingching Foocharoen\",\"doi\":\"10.1515/rir-2024-0014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Left ventricular systolic dysfunction (LVSD) is a cardiac involvement that is the leading cause of death among patients with systemic sclerosis (SSc). We aimed to define the clinical course and predictors of LVSD among SSc patients.</p><p><strong>Methods: </strong>We conducted a cohort study among adult patients with SSc who were followed up from 2013 to 2020. Semiparametric Cox regression analysis with robust clustering by cohort identification number was used to evaluate the predictors of LVSD.</p><p><strong>Results: </strong>Among the 3, 987 person-years, LVSD was defined in 35 of 419 SSc patients for an incidence of 0.88 per 100 person-years. The median duration of the disease was 8.5 (interquartile range (IQR) 4.9-12.9) years. Every 1-point increase in the modified Rodnan skin score (mRSS) and salt and pepper skin were strong predictors of LVSD, with a respective adjusted hazard ratio (HR) of 1.05 and 3.17. During follow-up, 26 cases (74.3%) had unimproved LVSD. The strong predictors of the unimprovement of LVSD were every 1-point increase in mRSS (HR 1.05), every 1 mg increase in prednisolone treatment (HR 1.05), and every 1 U/L increase in creatine kinase (CK) (HR 1.001). Mycophenolate treatment was a protective factor against the unimprovement of LVSD in SSc (HR 0.15).</p><p><strong>Conclusions: </strong>LVSD was frequently found in patients with diffuse cutaneous SSc, and in most cases, it remained unimproved during follow-up. High mRSS, steroid use, and high CK levels were predictors of unimproved LVSD, whereas mycophenolate treatment might prevent the progression of LVSD. Steroids should be prescribed with caution in patients with longer disease duration.</p>\",\"PeriodicalId\":74736,\"journal\":{\"name\":\"Rheumatology and immunology research\",\"volume\":\"5 2\",\"pages\":\"107-116\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11248551/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology and immunology research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/rir-2024-0014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology and immunology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/rir-2024-0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:左心室收缩功能障碍(LVSD)是一种心脏受累,是系统性硬化症(SSc)患者死亡的主要原因。我们旨在确定系统性硬化症患者左心室收缩功能障碍的临床过程和预测因素:我们对 2013 年至 2020 年随访的成年 SSc 患者进行了一项队列研究。采用半参数 Cox 回归分析法,通过队列识别号进行稳健聚类,评估 LVSD 的预测因素:在 3,987 人年中,419 名 SSc 患者中有 35 人定义了 LVSD,发病率为每 100 人年 0.88 例。中位病程为 8.5 年(四分位间距 (IQR) 4.9-12.9 年)。改良罗德南皮肤评分(mRSS)每增加 1 分以及盐和胡椒皮肤都是 LVSD 的有力预测因素,调整后的危险比(HR)分别为 1.05 和 3.17。随访期间,26 例(74.3%)患者的 LVSD 未见好转。mRSS每增加1点(HR 1.05)、泼尼松龙治疗每增加1毫克(HR 1.05)、肌酸激酶(CK)每增加1 U/L(HR 1.001)是预测LVSD未改善的有力因素。霉酚酸盐治疗是防止 SSc 患者 LVSD 无改善的保护因素(HR 0.15):结论:弥漫性皮肤SSc患者经常出现左心室退化症,在大多数病例中,随访期间左心室退化症仍未改善。高 mRSS、使用类固醇和高 CK 水平是 LVSD 未改善的预测因素,而霉酚酸盐治疗可预防 LVSD 的恶化。病程较长的患者应慎用类固醇。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical courses and predictors of left ventricular systolic dysfunction in systemic sclerosis: A cohort study.

Background and objectives: Left ventricular systolic dysfunction (LVSD) is a cardiac involvement that is the leading cause of death among patients with systemic sclerosis (SSc). We aimed to define the clinical course and predictors of LVSD among SSc patients.

Methods: We conducted a cohort study among adult patients with SSc who were followed up from 2013 to 2020. Semiparametric Cox regression analysis with robust clustering by cohort identification number was used to evaluate the predictors of LVSD.

Results: Among the 3, 987 person-years, LVSD was defined in 35 of 419 SSc patients for an incidence of 0.88 per 100 person-years. The median duration of the disease was 8.5 (interquartile range (IQR) 4.9-12.9) years. Every 1-point increase in the modified Rodnan skin score (mRSS) and salt and pepper skin were strong predictors of LVSD, with a respective adjusted hazard ratio (HR) of 1.05 and 3.17. During follow-up, 26 cases (74.3%) had unimproved LVSD. The strong predictors of the unimprovement of LVSD were every 1-point increase in mRSS (HR 1.05), every 1 mg increase in prednisolone treatment (HR 1.05), and every 1 U/L increase in creatine kinase (CK) (HR 1.001). Mycophenolate treatment was a protective factor against the unimprovement of LVSD in SSc (HR 0.15).

Conclusions: LVSD was frequently found in patients with diffuse cutaneous SSc, and in most cases, it remained unimproved during follow-up. High mRSS, steroid use, and high CK levels were predictors of unimproved LVSD, whereas mycophenolate treatment might prevent the progression of LVSD. Steroids should be prescribed with caution in patients with longer disease duration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信